This phase I/II study is investigating the effects of targeted therapy (BMS-986253) in combination with immunotherapy (nivolumab and/or ipilimumab) in people with advanced solid cancersA Phase 1/2 Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Summary

This study has 5 experimental arms across two phases. In Parts 1A and 1B, participants will receive BMS-986253 and nivolumab. In Part 1C, participants will receive BMS-986253 in combination with nivolumab and ipilimumab. In Part 2A, participants will receive BMS-986253 in combination with nivolumab and ipilimumab. In Part 2B, participants will receive a placebo in combination with nivolumab and ipilimumab.